Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial  Issaka Sagara, PhD, Abdoul Habib Beavogui, PhD, Issaka Zongo, PhD, Issiaka Soulama, PhD, Isabelle Borghini-Fuhrer, PhD, Bakary Fofana, MD, Daouda Camara, MSc, Anyirékun F Somé, PhD, Aboubacar S Coulibaly, MD, Oumar B Traore, MD, Niawanlou Dara, PharmD, Moïse J T Kabore, MD, Ismaila Thera, MSc, Yves D Compaore, MD, Malick Minkael Sylla, MD, Frederic Nikiema, MD, Mamadou Saliou Diallo, MD, Alassane Dicko, PhD, Jose Pedro Gil, PhD, Steffen Borrmann, MD, Stephan Duparc, MD, Robert M Miller, FRCS, Ogobara K Doumbo, PhD, Jangsik Shin, MSc, Anders Bjorkman, PhD, Jean-Bosco Ouedraogo, PhD, Sodiomon B Sirima, PhD, Prof Abdoulaye A Djimdé, PhD  The Lancet Infectious Diseases  Volume 16, Issue 2, Pages 189-198 (February 2016) DOI: 10.1016/S1473-3099(15)00318-7 Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

Figure 1 Trial profile The Lancet Infectious Diseases 2016 16, 189-198DOI: (10.1016/S1473-3099(15)00318-7) Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

Figure 2 Peak bilirubin versus peak alanine aminotransferase or aspartate aminotransferase on or after day 3 following first treatment (episode 1) or re-treatment (episode 2+) with pyronaridine-artesunate or artemether-lumefantrine ULN=upper limit of normal. The Lancet Infectious Diseases 2016 16, 189-198DOI: (10.1016/S1473-3099(15)00318-7) Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions

Figure 3 Incidence of adverse events after pyronaridine-artesunate for first malaria episode and re-treatment of subsequent malaria episodes by time from first treatment to re-treatment The Lancet Infectious Diseases 2016 16, 189-198DOI: (10.1016/S1473-3099(15)00318-7) Copyright © 2016 Sagara et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions